{"id":"abemaciclib-aromatase-inhibitor","safety":{"commonSideEffects":[{"rate":"86","effect":"Diarrhea"},{"rate":"46","effect":"Neutropenia"},{"rate":"37","effect":"Fatigue"},{"rate":"32","effect":"Nausea"},{"rate":"28","effect":"Abdominal pain"},{"rate":"17","effect":"Vomiting"},{"rate":"25","effect":"Anemia"},{"rate":"null","effect":"Arthralgia/myalgia"}]},"_chembl":{"chemblId":"CHEMBL3301610","moleculeType":"Small molecule","molecularWeight":"506.61"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Abemaciclib is a selective CDK4/6 inhibitor that prevents phosphorylation of the retinoblastoma protein, halting G1/S cell cycle transition in estrogen receptor-positive breast cancer cells. The combination with an aromatase inhibitor (which blocks estrogen synthesis) provides dual endocrine and cell cycle targeting, enhancing efficacy in hormone-dependent tumors. This combination is the basis of the marketed regimen for hormone receptor-positive, HER2-negative breast cancer.","oneSentence":"Abemaciclib inhibits CDK4/6 to block cell cycle progression in hormone receptor-positive breast cancer, while the aromatase inhibitor reduces estrogen production to further suppress tumor growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:21:38.250Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (first-line and subsequent lines)"},{"name":"Hormone receptor-positive, HER2-negative early breast cancer (adjuvant setting)"}]},"trialDetails":[{"nctId":"NCT05307705","phase":"PHASE1","title":"A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-05-11","conditions":"Breast Cancer","enrollment":193},{"nctId":"NCT07114601","phase":"PHASE1","title":"A Study of LY4257496 in Participants With Cancer (OMNIRAY)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-08-06","conditions":"Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm","enrollment":421},{"nctId":"NCT05573126","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","status":"RECRUITING","sponsor":"Ellipses Pharma","startDate":"2023-01-11","conditions":"Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer","enrollment":95},{"nctId":"NCT06650423","phase":"","title":"Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer","status":"RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2025-01-05","conditions":"Early Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer","enrollment":319},{"nctId":"NCT06830720","phase":"","title":"A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-02-20","conditions":"Breast Neoplasms","enrollment":3250},{"nctId":"NCT06366347","phase":"PHASE2","title":"ALPINE: Maintenance Letrozole/Abemaciclib","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-09-25","conditions":"Endometrial Cancer, Recurrent Endometrial Cancer, TP53","enrollment":32},{"nctId":"NCT04923542","phase":"PHASE1, PHASE2","title":"Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-11-30","conditions":"Brain Metastases, HR+ Metastatic Breast Cancer","enrollment":31},{"nctId":"NCT02763566","phase":"PHASE3","title":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2016-12-05","conditions":"Breast Cancer","enrollment":463},{"nctId":"NCT02246621","phase":"PHASE3","title":"A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2014-11-06","conditions":"Breast Cancer","enrollment":493},{"nctId":"NCT05305924","phase":"PHASE2","title":"Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2021-02-25","conditions":"ER-Positive Breast Cancer, HER2-negative Breast Cancer","enrollment":28},{"nctId":"NCT04964934","phase":"PHASE3","title":"Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-30","conditions":"ER-Positive HER2-Negative Breast Cancer","enrollment":315},{"nctId":"NCT06001762","phase":"PHASE2","title":"TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-10-05","conditions":"Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma","enrollment":90},{"nctId":"NCT04584853","phase":"PHASE3","title":"PreOperative Endocrine Therapy for Individualised Care With Abemaciclib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2020-12-23","conditions":"Breast Cancer Female","enrollment":123},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT07037199","phase":"PHASE2","title":"Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-18","conditions":"Advanced Breast Cancer","enrollment":45},{"nctId":"NCT06495164","phase":"","title":"A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-06-24","conditions":"Breast Cancer, Malignant Neoplasm of Breast","enrollment":1},{"nctId":"NCT04565054","phase":"PHASE3","title":"Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"West German Study Group","startDate":"2020-09-02","conditions":"Breast Cancer Female","enrollment":1260},{"nctId":"NCT05867251","phase":"PHASE1, PHASE2","title":"Study of AVZO-021 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Avenzo Therapeutics, Inc.","startDate":"2023-08-30","conditions":"Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer","enrollment":430},{"nctId":"NCT06139107","phase":"PHASE1","title":"RADIANT: Pre-op Radiation With Abemaciclib and Letrozole","status":"RECRUITING","sponsor":"Mridula George, MD","startDate":"2024-08-22","conditions":"Breast Cancer","enrollment":15},{"nctId":"NCT07190443","phase":"PHASE3","title":"Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)","status":"RECRUITING","sponsor":"Japanese Foundation for Cancer Research","startDate":"2025-02-07","conditions":"Breast Cancer, Locoregional Recurrence, Abemaciclib","enrollment":290},{"nctId":"NCT04681768","phase":"","title":"Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2020-12-22","conditions":"Breast Cancer/ Metastatic Breast Cancer","enrollment":95},{"nctId":"NCT04158362","phase":"PHASE3","title":"Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2020-06-11","conditions":"Cancer Metastatic","enrollment":180},{"nctId":"NCT03425838","phase":"PHASE3","title":"Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Borstkanker Onderzoek Groep","startDate":"2017-11-09","conditions":"Breast Neoplasm Female","enrollment":1050},{"nctId":"NCT04227327","phase":"PHASE2","title":"Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)","status":"TERMINATED","sponsor":"University of Milano Bicocca","startDate":"2020-01-07","conditions":"Advanced Breast Cancer","enrollment":31},{"nctId":"NCT04352777","phase":"PHASE2","title":"Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer","status":"COMPLETED","sponsor":"Duke University","startDate":"2020-09-14","conditions":"Metastatic Breast Cancer, Locally Advanced Breast Cancer, Hormone Receptor Positive Tumor","enrollment":18},{"nctId":"NCT05952557","phase":"PHASE3","title":"An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-10-05","conditions":"Breast Cancer, Early Breast Cancer","enrollment":5500},{"nctId":"NCT07005557","phase":"PHASE3","title":"Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-06-15","conditions":"Breast Cancer, Adjuvant Therapy","enrollment":1244},{"nctId":"NCT04188548","phase":"PHASE1","title":"A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2019-12-10","conditions":"Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":500},{"nctId":"NCT05362760","phase":"PHASE4","title":"Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management","status":"RECRUITING","sponsor":"Prof. Wolfgang Janni","startDate":"2022-04-27","conditions":"Hormone Receptor-positive Metastatic Breast Cancer, HER2-negative Metastatic Breast Cancer","enrollment":300},{"nctId":"NCT04660435","phase":"","title":"To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer","status":"RECRUITING","sponsor":"Fondazione Sandro Pitigliani","startDate":"2020-09-01","conditions":"Metastatic Breast Cancer, ER Positive Breast Cancer, HER2-negative Breast Cancer","enrollment":150},{"nctId":"NCT04256941","phase":"PHASE2","title":"Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-05-31","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8","enrollment":4},{"nctId":"NCT03227328","phase":"PHASE2","title":"CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2017-08-02","conditions":"Hormone Receptor Positive Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Negative Breast Cancer","enrollment":52},{"nctId":"NCT06341621","phase":"PHASE3","title":"Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-04-02","conditions":"Breast Cancer","enrollment":1900},{"nctId":"NCT05891093","phase":"PHASE3","title":"Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-01","conditions":"Breast Cancer","enrollment":766},{"nctId":"NCT04707196","phase":"PHASE4","title":"A Study of Abemaciclib in Indian Women With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-02-22","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":200},{"nctId":"NCT05789771","phase":"","title":"Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.","status":"COMPLETED","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2022-04-01","conditions":"HR+/HER2- Breast Cancer, Metastatic Disease, Аdvanced Disease","enrollment":136},{"nctId":"NCT04852081","phase":"","title":"Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2021-01-01","conditions":"Breast Cancer Stage IV","enrollment":1000},{"nctId":"NCT03846583","phase":"PHASE1","title":"Tucatinib + Abemaciclib + Herceptin for HER2+ MBC","status":"WITHDRAWN","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-06-28","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT04088032","phase":"EARLY_PHASE1","title":"Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer","status":"WITHDRAWN","sponsor":"Alison Stopeck","startDate":"2019-10-01","conditions":"Breast Cancer Female, Locally Advanced Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast","enrollment":""},{"nctId":"NCT03988114","phase":"PHASE4","title":"A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer","status":"WITHDRAWN","sponsor":"Eli Lilly and Company","startDate":"2019-09-16","conditions":"Metastatic Breast Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":95,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Verzenios"],"phase":"marketed","status":"active","brandName":"Abemaciclib + Aromatase Inhibitor","genericName":"Abemaciclib + Aromatase Inhibitor","companyName":"Prof. Wolfgang Janni","companyId":"prof-wolfgang-janni","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abemaciclib inhibits CDK4/6 to block cell cycle progression in hormone receptor-positive breast cancer, while the aromatase inhibitor reduces estrogen production to further suppress tumor growth. Used for Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (first-line and subsequent lines of therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}